1. Home
  2. HWBK vs SGHT Comparison

HWBK vs SGHT Comparison

Compare HWBK & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HWBK

Hawthorn Bancshares Inc.

HOLD

Current Price

$34.60

Market Cap

231.4M

Sector

Finance

ML Signal

HOLD

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$8.34

Market Cap

193.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HWBK
SGHT
Founded
1865
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
231.4M
193.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
HWBK
SGHT
Price
$34.60
$8.34
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$5.21
AVG Volume (30 Days)
6.4K
264.2K
Earning Date
01-21-2026
11-06-2025
Dividend Yield
2.29%
N/A
EPS Growth
259.86
N/A
EPS
3.19
N/A
Revenue
$77,904,000.00
$76,052,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$12.47
P/E Ratio
$10.92
N/A
Revenue Growth
45.83
N/A
52 Week Low
$25.21
$2.03
52 Week High
$35.95
$8.80

Technical Indicators

Market Signals
Indicator
HWBK
SGHT
Relative Strength Index (RSI) 75.39 66.52
Support Level $33.44 $8.09
Resistance Level $34.20 $8.68
Average True Range (ATR) 0.63 0.52
MACD 0.23 -0.00
Stochastic Oscillator 95.35 72.32

Price Performance

Historical Comparison
HWBK
SGHT

About HWBK Hawthorn Bancshares Inc.

Hawthorn Bancshares Inc is a financial holding company and along with its subsidiary, it conducts general banking and trust business, offering its customers checking and savings accounts, internet banking, certificates of deposit, trust services, brokerage services, and safety deposit boxes. The company also offers a range of lending services, including commercial and industrial loans, single payment personal loans, installment loans, and commercial and residential real estate loans.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Share on Social Networks: